We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Antipsychotika | SpringerLink

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content
SpringerLink
Log in

Antipsychotika

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antipsychotika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der ausführlichen Darstellung der Risiken und Nebenwirkungen der Antipsychotika.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Arasteh O, Nomani H, Baharara H et al (2020) Antipsychotic drugs and risk of developing venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis. Curr Vasc Pharmacol 18(6):632–643

    Article  CAS  PubMed  Google Scholar 

  • Arranz B, Garriga M, García-Rizo C, San L (2018) Clozapine use in patients with schizophrenia and a comorbid substance use disorder: a systematic review. Eur Neuropsychopharmacol 28(2):227–242

    Article  CAS  PubMed  Google Scholar 

  • Barnes TR, Leeson VC, Paton C et al (2017) Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technol Assess 21(49):1–56

    Article  PubMed  PubMed Central  Google Scholar 

  • Block TS, Kushner H, Kalin N et al (2018) Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biol Psychiatry 84(1):46–54

    Article  CAS  PubMed  Google Scholar 

  • Bosnjak Kuharic D, Kekin I, Hew J et al (2019) Interventions for prodromal stage of psychosis. Cochrane Database Syst Rev 2019(11):CD012236

    Google Scholar 

  • Çakici N, van Beveren NJM, Judge-Hundal G et al (2019) An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med 49(14):2307–2319

    Article  PubMed  PubMed Central  Google Scholar 

  • Correll CU, Rubio JM, Inczedy-Farkas G et al (2017) Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7):675–684

    Article  PubMed  PubMed Central  Google Scholar 

  • Demjaha A, Lappin JM, Stahl D et al (2017) Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 47(11):1981–1989

    Article  CAS  PubMed  Google Scholar 

  • DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde e. V.) (Hrsg) (2019) S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038-009. Langfassung, Stand: 15. März 2019. https://www.awmf.org/leitlinien/detail/ll/038-009.html

  • Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23:1023–1033

    Article  CAS  PubMed  Google Scholar 

  • Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188:255–263

    Article  PubMed  Google Scholar 

  • Galling B, Roldán A, Rietschel L et al (2016) Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf 15(5):591–612

    Article  CAS  PubMed  Google Scholar 

  • Galling B, Roldan A, Hagi K et al (2017) Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 16(1):77–89

    Article  PubMed  PubMed Central  Google Scholar 

  • Galling B, Vernon JA, Pagsberg AK et al (2018) Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 137(3):187–205

    Article  CAS  PubMed  Google Scholar 

  • Ghabrash MF, Coronado-Montoya S, Aoun J et al (2020) Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: a systematic review with a risk of bias assessment. Psychiatry Res 286:112890

    Article  CAS  PubMed  Google Scholar 

  • Gregory A, Mallikarjun P, Upthegrove R (2017) Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 211(4):198–204

    Article  PubMed  Google Scholar 

  • Hiemke C (2019) Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 41(2):174–179

    Article  PubMed  Google Scholar 

  • Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 174(3):216–229

    Article  PubMed  Google Scholar 

  • Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kane JM, Correll CU (2016) The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry 73(3):187–188

    Article  PubMed  Google Scholar 

  • Kennedy NI, Lee WH, Frangou S (2018) Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: a meta-analysis of randomized controlled trials. Eur Psychiatry 49:69–77

    Article  PubMed  Google Scholar 

  • Krause M, Zhu Y, Huhn M et al (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatr Clin Neurosci 268(7):625–639

    Article  Google Scholar 

  • Lally J, Tully J, Robertson D et al (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3):215–224

    Article  PubMed  Google Scholar 

  • Lally J, McCaffrey C, O’Murchu C et al (2019) Clozapine rechallenge following neuroleptic malignant syndrome: a systematic review. J Clin Psychopharmacol 39(4):372–379

    Article  PubMed  Google Scholar 

  • Leucht S, Davis JM (2017) Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 211(3):127–129

    Article  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896):951–962

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2):314–326

    Article  PubMed  PubMed Central  Google Scholar 

  • Leucht S, Leucht C, Huhn M et al (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927–942

    Article  PubMed  Google Scholar 

  • Leucht S, Chaimani A, Mavridis D et al (2019) Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology 44(11):1955–1966

    Article  PubMed  PubMed Central  Google Scholar 

  • Masood B, Lepping P, Romanov D, Poole R (2018) Treatment of alcohol-induced psychotic disorder (alcoholic hallucinosis) – a systematic review. Alcohol Alcohol 53(3):259–267

    Article  PubMed  Google Scholar 

  • Maust DT, Kim HM, Seyfried LS et al (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia. Jama Psychiatry 72:438–445

    Article  PubMed  PubMed Central  Google Scholar 

  • Mizuno Y, McCutcheon RA, Brugger SP, Howes OD (2020) Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology 45(4):622–631

    Article  CAS  PubMed  Google Scholar 

  • Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A et al (2018) Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 138(4):281–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Osoegawa C, Gomes JS, Grigolon RB et al (2018) Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res 197:34–44

    Article  PubMed  Google Scholar 

  • Pelzer AC, van der Heijden FM, den Boer E (2018) Systematic review of catatonia treatment. Neuropsychiatr Dis Treat 14:317–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pillinger T, Beck K, Gobjila C et al (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261–269

    Article  PubMed  PubMed Central  Google Scholar 

  • Pillinger T, McCutcheon RA, Vano L et al (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1):64–77

    Article  PubMed  PubMed Central  Google Scholar 

  • Sabe M, Kirschner M, Kaiser S (2019) Postdopaminergic drugs for treating the negative symptoms of schizophrenia. Systematic review and meta-analysis of randomized controlled trials.J Clin Psychopharmacol 39:658–664

    Article  CAS  PubMed  Google Scholar 

  • Sakurai H, Suzuki T, Bies RR et al (2016) Increasing versus maintaining the dose of olanzapine or risperidone in schizophrenia patients who did not respond to a modest dosage: a double-blind randomized controlled trial. J Clin Psychiatry 77(10):1381–1390

    Article  PubMed  Google Scholar 

  • Samara MT, Leucht C, Leeflang MM et al (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617–629

    Article  PubMed  Google Scholar 

  • Samara MT, Dold M, Gianatsi M et al (2016) Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. Jama Psychiatry 73(3):199–210

    Article  PubMed  Google Scholar 

  • Schneider-Thoma J, Efthimiou O, Huhn M et al (2018) Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 5(8):653–663

    Article  PubMed  Google Scholar 

  • Sinclair DJ, Zhao S, Qi F et al (2019) Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011847.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  • Sondergaard KB, Weeke P, Wissenberg M et al (2017) Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3(2):100–107

    PubMed  Google Scholar 

  • Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125:15–24

    Article  CAS  PubMed  Google Scholar 

  • Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6):600–606

    Article  PubMed  Google Scholar 

  • Tiihonen J, Mittendorfer-Rutz E, Majak M et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29.823 patients with schizophrenia. JAMA Psychiatry 74(7):686–693

    Article  PubMed  PubMed Central  Google Scholar 

  • Tiihonen J, Taipale H, Mehtälä J et al (2019) Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76(5):499–507

    Article  PubMed  PubMed Central  Google Scholar 

  • Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41:656–636

    Article  PubMed  Google Scholar 

  • Williams AM (2018) Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Ment Health Clin 8(5):208–213

    Article  PubMed  PubMed Central  Google Scholar 

  • Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and selfharm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174:990–998

    Article  PubMed  Google Scholar 

  • Yoshimura B, Sakamoto S, Sato K et al (2017) Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study. Early Interv Psychiatry 250:65–70

    CAS  Google Scholar 

  • Yunusa I, Alsumali A, Garba AE et al (2019) Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open 2(3):e190828

    Article  PubMed  PubMed Central  Google Scholar 

  • Zeller S, Zun L, Cassella JV et al (2017) Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. BJPsych open 3(6):285–290

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin, Deutschland

    Prof. Dr. med. Dr. rer. nat. Matthias J. Müller

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. med. Dr. rer. nat. Matthias J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Müller, M.J., Benkert, O. (2021). Antipsychotika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation